

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>G01N 27/327, C12Q 1/00, G01N 33/543, B01D 71/28</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/43633</b> <b>(43) International Publication Date:</b> 20 November 1997 (20.11.97)
<b>(21) International Application Number:</b> PCT/US97/08648			<b>(81) Designated States:</b> AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
<b>(22) International Filing Date:</b> 16 May 1997 (16.05.97)			
<b>(30) Priority Data:</b> 08/602,909 17 May 1996 (17.05.96) US			
<b>(60) Parent Application or Grant</b> (63) Related by Continuation US 08/602,909 (CON) Filed on 17 May 1996 (17.05.96)			
<b>(71) Applicant (for all designated States except US):</b> ENCELLE, INC. [US/US]; 545 Hannah Building, Cleveland, OH 44115 (US).		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> USALA, Anton-Lewis [US/US]; 237 Buckingham Drive, Winterville, NC 28590 (US).			
<b>(74) Agents:</b> SIBLEY, Kenneth, D. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).			

**(54) Title:** ELECTROCHEMICAL BIOSENSORS**(57) Abstract**

An electrochemical biosensor for determining the level of a target chemical in a biological fluid includes an electrochemical system including an enzyme substrate which reacts with the target chemical to yield a system signal related to the concentration in the biological fluid of said target chemical. The biosensor includes a first membrane for immobilizing the enzyme substrate. The first membrane has a porosity permitting passage therethrough of the target chemical to react with the enzyme substrate and a surface exposed to the biological fluid characterized by electron donor site susceptible to facilitating attachment thereon of proteins and fibrin which impair the system signal. A second membrane is bonded to the electron donor sites of the first membrane. The second membrane is formed of a phenyl based polymer having connecting hydrogen atom donors which bond to the hydrogen atom donors bonding to the electron donor sites at least sufficiently to form an outer surface on the first membrane exposed to the biological fluid consisting of phenyl rings without significantly changing the porosity provided by the first membrane.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	CN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

## ELECTROCHEMICAL BIOSENSORS

### FIELD OF THE INVENTION

The present invention relates to means for detecting a broad range of chemicals and biological substances that may be found in blood or other 5 physiological fluids including electrochemical biosensors for determining the levels of chemicals in biological fluids, and in particular, an implantable glucose sensor for determining in vivo the concentration of blood glucose levels.

10

### BACKGROUND OF THE INVENTION

Electrochemical biosensors are used, both in vitro and in vivo, to determine the levels of chemicals in biological fluids. For example, blood glucose sensors are used to determine the concentration of 15 glucose in blood sera. Oxygen sensors are used to measure oxygen levels in blood. Other examples are potassium, calcium, pH, CO<sub>2</sub>, sodium, chloride sensors and the like. Such sensors use an enzyme, immobilized by a membrane sheathing, coupled to an electrochemical 20 system. The target chemical in the biological fluid reacts with the enzyme to generate a current signal related to the target chemical concentration, which signal is processed by the system to provide an output indicative thereof.

25

While well defined for in vitro testing and used routinely therefor, there has been a long-felt need in the art for implantable or indwelling biosensors that can function, reliably without drift or recalibrating caused by biological overgrowth and 30 attachment, for extended times in recipient patients. Implantable glucose sensors were first proposed in the 1960's (Gough et al., Diabetes, Vol. 44, pp.190-198). However, to date no successful biosensor has been developed notwithstanding advances which have yielded

-2-

successful in vitro versions which function for somewhat extended periods but are prone to biological overgrowth and fouling. Such biosensors are well characterized in the art and generally fall into the 5 categories of hydrogen peroxide-based enzyme electrode sensors, oxygen-based enzyme electrode sensors, mediator-based enzyme electrode sensors, membrane covered catalytic electrodes and others.

The most significant reason for an inability 10 to function reliably long-term in vivo appears to be biological fouling of the electrode membrane resulting in a progressive reduction in sensing area and resultant drift in electrical signal, ultimately leading to complete blockage of the membrane and the 15 loss of meaningful signal. These membranes currently function adequately in most regards. Examples of such membranes include polyurethane, cellulose acetate, perfluorosulfonic acid polymer (Nafion®), and other like membrane materials. Such membranes are considered 20 biocompatible in the sense that they do not elicit an inflammatory response in the host. However, these membrane materials have reactive groups which provide attachment sites for biological overgrowth leading to the membrane fouling discussed above.

25 It would thus be desirable to provide an electrochemical biosensor based on current and future designs while protecting the membrane from performance-degrading biological overgrowth.

#### SUMMARY OF THE INVENTION

30 The present invention achieves the above and other significant objectives and provides an improved electrochemical biosensor that limits biological overgrowth and attachment to the membrane and permits extended indwelling determination of target biological 35 chemicals. This is achieved by passivating the biological active sites on the membrane without

-3-

significantly affecting the functional properties of the membrane, i.e., porosity and diffusion. This is achieved by applying a second membrane over the first membrane, the second membrane being characterized by a 5 phenyl-based polymer having connecting hydrogen donors bonded to the biologically active sites on the first polymer without significantly affecting the properties of the first membrane. Preferably, the polymer is selected from the parylene family including 10 poly-para-xylylene, mono-chloropoly-para-xylylene, dichloro-poly-para-xylylene and analogs thereof. The parylene membrane is vacuum deposited on the outer surface of the first membrane in an amount sufficient to occupy the biologically active sites to an extent 15 limiting biological attachment but not significantly affecting the electrochemical performance of the biosensor.

For example, polyurethane membranes have shown some promise as a membrane for glucose sensors. 20 However, the outer surfaces of such membranes have bioactive attachment sites, i.e., oxygen and hydrogen, each of which is well recognized for supporting protein and fibrin attachment. The parylene polymers used in the present invention are phenyl-based polymers having 25 connecting CH<sub>2</sub> groups. Other similar polymers have connecting -NH- groups, -SH- groups or other limited hydrogen atom donors. These phenyl-based polymers such as poly-para-xylylene, adhere to the underlying surface by hydrogen bonding between the connecting CH<sub>2</sub> groups 30 and an oxygen, fluorine, chlorine, or other electron donor on the base membrane substrate. Such hydrogen bonding leaves only the phenyl rings exposed to the surrounding milieu, and thus precludes attachment sites from circulating proteins or cells that would otherwise 35 attach thereto, thereby degrading the sensitivity and accuracy of the electrochemical reaction and resultant signal.

-4-

As set forth in greater detail below, a biosensor employing an improved membrane in accordance with the present invention, when implanted in-vivo and removed for testing, yielded a membrane without protein or fibrin attachment. Pre-implant readings and post-implant readings showed a high degree of correlation. In contrast, an uncoated control sensor membrane was occluded with fibrin and protein attachment so as to preclude post removal readings.

10 The use of the phenyl ring polymers herein differs from the approach taken in copending application United States Serial Number 346,340 filed on November 28, 1994 and assigned to the assignee of the present invention. Therein a membrane of the 15 parylene family of polymers was used as a semi-permeable membrane to protect cellular moieties from the patient immune system while allowing cell nutrients, chemical signals for the cellular production, and the chemical moiety produced thereby to 20 flow through the membrane. The thickness of the polymer was the prime determinant of membrane porosity and membrane strength and desirable membranes were produced in the 2,000 to 5,000 Angstroms for monolithic membranes. In contrast, the membrane for providing 25 biological passivation in the present invention is an order or orders of magnitudes thinner to produce the desired porosity, generally 1,000 Angstroms or below depending on the base membrane material. Such an ultra thin membrane would normally not have sufficient 30 mechanical strength to withstand the biological forces of implantation. This is achieved in the present invention because the membrane is deposited conformally and preferentially at the attraction sites on the base membrane, rather than by the cross linking network of 35 only the base polymer. In other words, the base membrane functions more or less like a template for the biologically inert membrane until the active sites are

-5-

occupied. Depending on the overall properties desired, the coating may be applied in a manner in which only a portion of the sites are bonded to provide the desired biological inertness as needed. The membrane may also 5 be applied in excess to the extent that the desired membrane performance characteristics are not adversely affected.

Accordingly, the present invention provides an electrochemical biosensor for determining the level 10 of a target chemical in a biological fluid wherein an electrochemical system includes a substrate which reacts with the target chemical to yield a system signal related to the concentration in the biological fluid of said target chemical. A first membrane on the 15 biosensor immobilizes the substrate and has a porosity permitting passage therethrough of the target chemical to react with the substrate. The first membrane has a surface exposed to the biological fluid, said membrane being characterized by electron donor sites susceptible 20 to facilitating attachment thereon of proteins and fibrin, thus impairing the system signal. A second membrane is bonded to the electron donor sites of said first membrane. The second membrane is formed of a phenyl-based polymer having connecting hydrogen atom 25 donors which bond to the electron donor sites at least sufficiently to form an outer surface on the first membrane exposed to the biological fluid without significantly changing the porosity provided by the first membrane.

30 Further, the present invention provides a biologically inert membrane composite substrate including a first membrane characterized by a predetermined porosity and formed of a material with biologically active surface sites capable of supporting 35 protein and tissue attachment when exposed to biological fluids. A second membrane consisting of a phenyl-based polymer having connecting hydrogen donors

-6-

is bonded to the biologically active surface sites sufficiently to render such sites biologically inert without significantly affecting the predetermined porosity of the first membrane.

5        Moreover, the present invention provides a method for biologically passivating a membrane having a porosity permitting passage therethrough of a chemical in a biological fluid and a surface with attractive sites for proteins and fibrin, wherein a phenyl-based  
10      polymer having connecting hydrogen bond donors is bonded to the attractive sites in an amount sufficient to render the surface biologically inert but insufficient to impair passage through said membrane of said chemical.

15

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other features and advantages of the present invention will become apparent upon reading the following detailed description of the preferred embodiments taken in conjunction with the  
20      accompanying drawings in which:

Figure 1 is a diagrammatic drawing of a biosensor in accordance with the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Referring to the drawings for the purpose of  
25      describing preferred embodiments of the present invention, Figure 1 is a diagrammatic view of an electrochemical biosensor 10 for determining the levels of chemicals in biological fluids. The embodiments are described with reference to an implantable glucose  
30      sensor for determining the concentration of glucose in blood sera. However, it will be appreciated that electrochemical biosensors for determining the presence of other target chemicals in fluids including oxygen, potassium, calcium, acid, base, protons, CO<sub>2</sub>, sodium, chlorine and the like are within the scope of the  
35

- 7 -

features and advantages provided by the present invention.

The biosensor 10 may take any recognized form such as disclosed in the aforementioned Gough et al. 5 publication and will be described with reference to the model set forth in Gough et al., *Diabetes Care*, Vol. 5, No. 3, May-June 1982, pp. 190-198, which is incorporated herein by reference. Therein, the biosensor 10, immersed in a biological fluid 11, 10 comprises an oxygen electrode 12 covered by a base membrane 14 containing an immobilized enzyme layer 16. The enzyme layer 16 comprises glucose oxidase and catalase. In the presence of glucose and oxygen, the electrode 12 produces a glucose-modulated, oxygen 15 dependent current. It will be appreciated that this layer is not limited to an enzyme per se but in other applications may be any compound that reacts with another compound in a predictable and quantitatively measurable manner; or in other words, a specific 20 binding pair. The enzyme layer 16 is separated from the electrode 12 by a hydrophobic, oxygen-permeable layer 18. The membrane is formed of a biocompatible material such as polyurethane with a permeability that restricts access of macromolecules to the underlying 25 layers. The layer 18 is a hydrophobic, oxygen-permeable membrane that prevents electrode fouling due to the hydrophilic electroactive molecules in biological fluids. A spacer 20 separates the electrode 12 from a counter electrode 22. The electrodes 12 and 30 22 are connected to an electrical system 23 by leads 24 and 26 and delivering thereto a current flux related to the electrochemical reactions within the biosensor. Additionally, the electrical system is connected to a 35 reference electrode 28. As discussed in greater detail in the above publication, the system 23 outputs information related to the concentration of glucose in the biological fluid. The various laminae are enclosed

-8-

by a housing, not shown. In the present invention, the outer surface of the base membrane 14 is covered by a biologically inert membrane 30.

As mentioned above, various materials have 5 been proposed for biosensor membranes. Among the more prevalent membranes are polyurethane, cellulose acetate, perfluorosulfonic acid polymer and others well known in the art. Many of these materials are biocompatible in that the materials do not induce 10 inflammation when implanted. However, these materials have well-recognized bioattractive sites that for proteins and fibrin facilitate a biological overgrowth that results in a progressive reduction in sensing area and resultant drift in electrical signal, ultimately 15 leading to complete blockage of the membrane and loss of meaningful signal. These attractive sites typically have repeating electron donor sites including oxygen, fluorine, chlorine and the like.

In the present invention, the biologically 20 inert membrane 30 is formed of a material characterized by a phenyl-based polymer having connecting hydrogen donors that bond to the biologically active sites, thereby presenting to the biological fluid 11 a surface comprised of non-reactive phenyl rings. A preferred 25 membrane material is selected from the parylene family of polymers, including poly-para-xylylene, mono-chloro-para-xylylene, dichloro-para-xylylene and analogs thereof. The parylene polymers have connecting  $\text{CH}_2$  groups. Other similar polymers have -NH- groups, 30 -SH- groups and other limited hydrogen atom donors. These polymers bind to the active sites on the base membrane polymer through hydrogen bonding at the connecting groups. This is generally achieved with an ultra thin layer of the inert membrane material, 35 typically 1000 Angstroms or less, and generally between 50-500 Angstroms. At this thickness, the material, vacuum deposited in the case of the parylene polymers,

- 9 -

is applied preferentially to the active sites on the base polymer and believed substantially to the exclusion of cross linking with itself in a manner which renders the composite membrane biologically inert 5 without affecting the desired membrane properties, such as permeability and porosity.

It does not appear necessary that the membrane 30 completely passivate all the active sites. There may be instances where a less than complete 10 coating will provide biological protection sufficient for the membrane application. Also, the membrane may be applied in excess of the amount needed for inertness. However, the thickness should be controlled to prevent a diminution of membrane performance. 15 The aforementioned membrane thus provides biological passivation without a diminution of sensor sensitivity as demonstrated by the following examples.

#### Example 1

A pCO<sub>2</sub> membrane (available from NOVA 20 Biomedical, Waltham MA as catalog no. 07543) was coated with about 500 Angstroms of poly-para-xylylene to form a second membrane thereon. The coated membrane was tested in RPMI media on a NOVA Stat Profile 5 blood gas analyzer which combines blood gas and related stat 25 tests of serum, plasma, whole blood and expired gas for in vitro diagnostic use. The biosensor was tested in 7 consecutive trials and indicated pCO<sub>2</sub> levels of 32.04 STD 1.15. A similar not coated membrane was tested in 6 consecutive trials and indicated pCO<sub>2</sub> levels of 28.63 30 STD 5.96. It is thus apparent that second membrane did not affect biosensor readability and reliability.

#### Example 2

A pO<sub>2</sub> Membrane (available from NOVA 35 Biomedical, Waltham MA as catalog no. 11099) was coated with about 500 Angstroms of poly-para-xylylene to form

-10-

a second membrane thereon. The coated membrane was tested in RPMI media on a NOVA Stat Profile 5 blood gas analyzer which combines blood gas and related stat tests of serum, plasma, whole blood and expired gas for 5 in vitro diagnostic use. The biosensor was tested in 7 consecutive trials and indicated  $pO_2$  levels of 247.94 STD 4.44. A similar not coated membrane was tested in 6 consecutive trials and indicated  $pO_2$  levels of 251.41 STD 16.39. As in the first example, it is thus 10 apparent that second membrane did not affect biosensor readability and reliability.

Example 3

A glucose membrane (available from NOVA Biomedical, Waltham MA as catalog no. 08469) was coated 15 with less than about 500 Angstroms of poly-para-xylylene to form a second membrane thereon. The coated membrane was tested in a NOVA Stat Profile 5 blood gas analyzer which combines blood gas and related stat tests of serum, plasma, whole blood and expired 20 gas for in vitro diagnostic use. The biosensor was tested in 8 consecutive trials and indicated glucose levels of 207.7 mg% STD 1.59. A similar uncoated membrane was tested in 10 consecutive trials and indicated glucose levels of 200.5 mg% STD 1.59. It is 25 thus apparent that second membrane did not affect biosensor readability and reliability.

Thereafter the coated membrane and the uncoated membrane were implanted into a 4 kg New Zealand White rabbit with the membranes exposed 30 subcutaneously. The membranes were removed after 21 hours. The uncoated membrane was occluded and overgrown with tightly adhering hematocrit which was not dislodged by repeated washings and had to be physically removed for testing. The membrane was 35 tested in 8 trials and indicated glucose levels of 188.25 mg% STD 5.07. The coated membrane was

-11-

essentially clear of any fouling and was readily washed in normal saline solution. The coated membrane was tested in 8 trials and indicated glucose levels of 207.25 mg% STD .7. The foregoing indicates that the 5 uncoated membrane was adversely affected in short term implant due to biofouling whereas the membrane coated in accordance with the present invention was not subject to biofouling and did not experience any diminution in signal.

10        In addition to the aforementioned applications, it will be apparent to those skilled in the art that the composite membrane may be used in other biological applications wherein it is desired to protect cellular and chemical moieties from biological 15 fouling while providing desired porosity and diffusions. Examples of such applications include indwelling chemical sensors, indwelling electrical sensors, long term drug delivery carriers that must be free from fibrin or protein occlusion to release their 20 active ingredients or release the active agent in response to a stimulating moiety found in vivo.

While the present invention has been described with the detection of chemical and biological substances that are normally, abnormally, or 25 pathologically present in the blood or other physiological fluids, and whose detection may be desired on a continuing basis, these chemical or biological substances may be naturally occurring within the subject in which the biosensor is implanted, or by 30 unusual occurrence because of disease or reaction to physiological stress. Examples of such chemical and biological substances include, but are not limited to, hormones, peptides, proteins, glycoproteins, triglycerides, fats, lipids, polysaccharides, 35 carbohydrates, vitamins, minerals, therapeutics, and metals.

-12-

As used herein, a "hormone" is defined as a biological substance secreted by a specific tissue, and includes those substances having activity at a different site than the site of secretion and 5 precursors thereof, and substances having activity at the site of secretion (sometimes called autocoids), and secreted by the pituitary gland (or adenohypophysis), and specifically include the growth hormones (GH), melanocyte-stimulating hormones, somatomedins, and 10 lipotropins.

The biosensor of the present invention may also be useful in the detection of compounds that are normally found within the brain and which secrete neurologically active substances. Therefore, the 15 detection of neuropeptides may be provided in the practice of the invention, including the detection of neuropeptide families of the endorphins, the glucagon-secretins, and the substance-P neuropeptides. Endorphins include the proopiomelanocortins, the 20 proenkephalins, the prodynorphins and hormones derived therefrom. The glucagon-secretins include glucagon, vasoactive intestinal polypeptide (both found in pancreatic islets), secretin and growth hormone releasing factor (GHRF). The substance-P neuropeptides 25 include vasotocin, vasopressin and oxytocin. It is specifically intended that the detection of substances secreted by single large clusters of neurons (such as oxytocin, vasopressin, LHRH, GHRH, and proopiomelanocortin) are embraced by the scope of the 30 invention, as well as the detection of substances secreted by cells normally distributed throughout the brain (such as somatostatin, cholecystokinin and enkephalin).

The continuing detection of vitamins present 35 in blood and other fluids is another aspect of the invention. This aspect is particularly useful in monitoring vitamin levels in subjects who are at risk

-13-

for vitamin deficiencies. Such vitamins include vitamin A, thiamine, riboflavin, nicotinic acid, vitamin B<sub>6</sub>, vitamin D, iron, folic acid, and vitamin B<sub>12</sub>. The detection of vitamins via their reactions with 5 specific enzymes is known. For example, the presence of thiamine can be detected by its reaction with the enzymes erythrocyte transketolase (ETK) and thiamine pyrophosphate (TPP). Similarly, the presence of riboflavin may be detected by its known reaction with 10 erythrocyte glutathione reductase (EGR). Vitamin B<sub>6</sub> may be detected by its reaction with erythrocyte glutamic-oxaloacetic transaminase (EGOT), and vitamin D may be detected by its reaction with serum alkaline phosphatase.

15       Antibodies which may be detected by the biosensor of the present invention include those of the immunoglobulin family, including IgA, IgD, IgE, IgG and IgM. The detection of other immunological compounds and cells are a further aspect of this invention. 20 These other immunological compounds and cells include interleukins, cytokines, major histocompatibility complexes (MHC), T cells, complement, and macrophages.

25       The presence of drugs, other therapeutics and their metabolites may be detected by the biosensor of the present invention by known individual reactions with drug-specific enzymes and other reactive compounds. By drugs is meant any pharmaceutical with an intended and known therapeutic or diagnostic value, but may also mean an illegal or controlled substance 30 whose detection is desired for forensic or monitoring reasons.

35       The present invention is concerned primarily with the treatment of human subjects, but may also be employed for the treatment of other mammalian subjects, such as cows, pigs, goats, cats, and dogs, for veterinary purposes, or where compounds detected by the

- 14 -

biosensor are being produced in the animal for subsequent collection and the like.

One embodiment of the invention is the use of an electrobiochemical biosensor to detect substances 5 such as hormones, glucose, drugs, and the like in animals, for veterinary and/or agricultural purposes. As an example, growth hormones are sometimes administered to an animal subject for the purpose of increasing meat production. However, at excessively 10 high concentrations, such a hormone may cause deleterious effects in the consumer. A biosensor provided by the present invention which comprises a substrate reactive with such a hormone may therefore be implanted in such a meat-producing animal to provide a 15 means of monitoring such levels on an ongoing basis.

Various modifications of the above described embodiments will be apparent to those skilled in the art. Accordingly, the scope of the invention is defined only by the accompanying claims.

-15-

WHAT IS CLAIMED IS:

1. An electrochemical biosensor for determining the level of a target chemical in a biological fluid, said biosensor comprising:

an electrochemical system including a  
5 substrate which reacts with the target chemical to yield a system signal related to the concentration in the biological fluid of said target chemical;

10 a first membrane immobilizing said substrate and having a porosity permitting passage therethrough of the target chemical to react with said substrate said first membrane having a surface characterized by electron donor sites susceptible to facilitating attachment thereon of proteins and fibrin, thus impairing said system signal; and

15 a second membrane bonded to said electron donor sites of said first membrane, said second membrane being formed of a phenyl-based polymer having connecting hydrogen atom donors, said hydrogen atom donors bonding to said electron donor sites of said 20 first membrane at least sufficiently to form an outer surface on said first membrane without significantly changing the porosity provided by said first membrane, wherein said outer surface is exposed to the biological fluid and consists of phenyl rings.

25 2. A biologically inert membrane composite substrate, comprising:

a first membrane characterized by a predetermined porosity and formed of a material having biologically active surface sites capable of supporting 30 protein and tissue attachment when exposed to biological fluids; and

a second membrane consisting of a phenyl-based polymer having connecting hydrogen donors bonded to said biologically active surface sites sufficiently

-16-

to render said sites biologically inert without significantly affecting said predetermined porosity of said first membrane.

3. A method for biologically passivating a  
5 membrane having a porosity permitting passage therethrough of a chemical in a biological fluid and a surface with attractive sites for proteins and fibrin, comprising applying to said membrane a phenyl-based polymer having connecting hydrogen bond donors bonded  
10 to said attractive sites in an amount sufficient to render said surface biologically inert but insufficient to impair passage through said membrane of said chemical.

4. An electrochemical biosensor according  
15 to Claim 1, wherein said phenyl-based polymer is a parylene polymer.

5. An electrochemical biosensor according to Claim 1, wherein said phenyl-based polymer is selected from the group consisting of poly-para-  
20 xylylene, mono-chloro-para-xylylene and dichloro-para-xylylene.

6. An electrochemical biosensor according to Claim 1, wherein said second membrane has a thickness of less than about 1000 Angstroms.

25 7. An electrochemical biosensor according to Claim 1, wherein said second membrane has a thickness of between about 50 and about 500 Angstroms.

8. An electrochemical biosensor according to Claim 1, wherein said target chemical is glucose.

-17-

9. An electrochemical biosensor according to Claim 1, wherein said substrate comprises glucose oxidase.

10. A biologically inert membrane composite  
5 substrate according to Claim 2, wherein said phenyl-  
based polymer is a parylene polymer.

11. A biologically inert membrane composite  
substrate according to Claim 2, wherein said phenyl-  
based polymer is selected from the group consisting of  
10 poly-para-xylylene monochloro-para-xylylene and  
dichloro-para-xylylene.

12. A biologically inert membrane composite  
substrate according to Claim 2, wherein said second  
membrane has a thickness of less than about 1000  
15 Angstroms.

13. A biologically inert membrane composite  
substrate according to Claim 2, wherein said second  
membrane has a thickness of between about 50 and about  
500 Angstroms.

20 14. A method according to Claim 3, wherein  
said phenyl-based polymer is a parylene polymer.

15. A method according to Claim 3, wherein  
said phenyl-based polymer is selected from the group  
consisting of poly-para-xylylene, mono-chloro-para-  
25 xylylene and dichloro-para-xylylene.

16. A method according to Claim 3, wherein  
said phenyl-based polymer is applied to said membrane  
by vacuum deposition.

-18-

17. A membrane for providing biological passivation, said membrane comprising a phenyl-based polymer.

18. The membrane of Claim 17 wherein said 5 phenyl-based polymer is selected from the group consisting of polyphenyl, poly-para-xylylene, mono-chloro-para-xylylene and dichloro-para-xylylene.

19. The membrane of Claim 18, wherein said polymer has connecting groups selected from the group 10 consisting of H, CH<sub>2</sub>, SH, and NH.

20. The membrane of Claim 19, wherein said membrane has a thickness of less than about 1000Å.

21. A method for protecting cellular and chemical moieties from biological fouling comprising 15 surrounding said moieties with a membrane comprising a phenyl-based polymer.

22. The method of Claim 21 wherein said phenyl-based polymer is selected from the group consisting of polyphenyl, poly-para-xylylene, mono- 20 chloro-para-xylylene and dichloro-para-xylylene.

23. The method of Claim 22, wherein said polymer has connecting groups selected from the group consisting of H, CH<sub>2</sub>, SH, and NH

24. The method of Claim 23, wherein said 25 membrane has a thickness of less than about 1000Å.

25. A cellular or chemical moiety which has been coated with a membrane, said membrane comprising a phenyl-based polymer.

-19-

26. The moiety of Claim 25 wherein said phenyl-based polymer is selected from the group consisting of polyphenyl, poly-para-xylylene, mono-chloro-para-xylylene and dichloro-para-xylylene.

5 27. The moiety of Claim 26, wherein said polymer has connecting groups selected from the group consisting of H, CH<sub>2</sub>, SH, and NH.

28. The membrane of Claim 27, wherein said membrane has a thickness of less than about 1000Å.

1/1




FIG. 1.

**INTERNATIONAL SEARCH REPORT**

International Application No

PCT/US 97/08648

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 G01N27/327 C12Q1/00 G01N33/543 B01D71/28

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 6 C12Q G01N B01D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ELECTROANALYSIS, vol. 6, no. 5/6, May 1994, pages 423-429, XP002040030 D. CENTONZE ET AL: "Permeation of solutes through an electropolymerized ultrathin poly-o-phenylenediamine film used as an enzyme-entrapping membrane." see the whole document --- EP 0 259 109 A (ADVANCED POLYMER TECHNOLOGY) 9 March 1988 see the whole document --- US 5 151 183 A (SEDATH ROBERT H ET AL) 29 September 1992 see the whole document ---	1-3,17, 21  2,3,17  2,3,17 -/-
X		

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

8 September 1997

23.09.97

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Moreno, C

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/08648

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 16002 A (ALLIED SIGNAL INC) 21 July 1994 see the whole document ---	2
X	US 4 788 271 A (HERGENROTHER PAUL M ET AL) 29 November 1988 see the whole document ---	25
A	US 4 794 090 A (PARHAM MARC E ET AL) 27 December 1988 see the whole document ---	2,3,17, 21,25
A	WO 92 10584 A (NEDERLANDSE ORG TOEGEPAST) 25 June 1992 see the whole document ---	1
A	EP 0 138 150 A (DU PONT) 24 April 1985 see the whole document ---	1
A	WO 93 13408 A (ABBOTT LAB) 8 July 1993 see the whole document -----	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/08648

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0259109 A	09-03-88	US 4756835 A JP 63069503 A	12-07-88 29-03-88
US 5151183 A	29-09-92	EP 0472596 A JP 4505277 T WO 9014149 A	04-03-92 17-09-92 29-11-90
WO 9416002 A	21-07-94	AU 5957094 A CA 2153973 A CN 1091678 A EP 0679167 A JP 8508758 T US 5643968 A	15-08-94 21-07-94 07-09-94 02-11-95 17-09-96 01-07-97
US 4788271 A	29-11-88	NONE	
US 4794090 A	27-12-88	NONE	
WO 9210584 A	25-06-92	NL 9002764 A DE 69104496 D DE 69104496 T EP 0561966 A US 5422246 A	01-07-92 10-11-94 23-02-95 29-09-93 06-06-95
EP 0138150 A	24-04-85	CA 1219908 A JP 60097250 A	31-03-87 31-05-85
WO 9313408 A	08-07-93	AU 3274693 A US 5326449 A	28-07-93 05-07-94

**THIS PAGE BLANK (USPTO)**